74 related articles for article (PubMed ID: 21286719)
1. Extreme acute radiation-induced toxicity in a patient with polymorphous low-grade adenocarcinoma of the nasopharynx and rare variants in DNA repair genes.
Nowicka Z; Kuna K; Stawiski K; Sołek J; Świderek M; Papis-Ubych A; Fijuth J; Fendler W; Tomasik B
Head Neck; 2024 Feb; 46(2):E10-E17. PubMed ID: 37867397
[TBL] [Abstract][Full Text] [Related]
2. Significant Association Between XRCC1 Expression and Its rs25487 Polymorphism and Radiotherapy-Related Cancer Prognosis.
Gong L; Luo M; Sun R; Qiu L; Chen C; Luo Z
Front Oncol; 2021; 11():654784. PubMed ID: 34094945
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of single nucleotide polymorphisms in
Zhao J; Zhi Z; Zhang M; Li Q; Li J; Wang X; Ma C
Onco Targets Ther; 2018; 11():3901-3918. PubMed ID: 30013370
[TBL] [Abstract][Full Text] [Related]
4. ERCC2 polymorphisms and radiation-induced adverse effects on normal tissue: systematic review with meta-analysis and trial sequential analysis.
Song YZ; Duan MN; Zhang YY; Shi WY; Xia CC; Dong LH
Radiat Oncol; 2015 Dec; 10():247. PubMed ID: 26627042
[TBL] [Abstract][Full Text] [Related]
5. What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.
Petkova R; Chelenkova P; Georgieva E; Chakarov S
Biotechnol Biotechnol Equip; 2014 Jan; 28(1):2-7. PubMed ID: 26019482
[TBL] [Abstract][Full Text] [Related]
6. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.
Rednam S; Scheurer ME; Adesina A; Lau CC; Okcu MF
Pediatr Blood Cancer; 2013 Apr; 60(4):593-8. PubMed ID: 23065688
[TBL] [Abstract][Full Text] [Related]
7. Multi-modality therapy for cancer of the esophagus and GE junction.
Tejani MA; Burtness BA
Curr Treat Options Oncol; 2012 Sep; 13(3):390-402. PubMed ID: 22592595
[TBL] [Abstract][Full Text] [Related]
8. Genetics and genomics of radiotherapy toxicity: towards prediction.
West CM; Barnett GC
Genome Med; 2011 Aug; 3(8):52. PubMed ID: 21861849
[TBL] [Abstract][Full Text] [Related]
9. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Bates BA; Detterbeck FC; Bernard SA; Qaqish BF; Tepper JE
J Clin Oncol; 1996 Jan; 14(1):156-63. PubMed ID: 8558191
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group.
Yoon HH; Catalano P; Gibson MK; Skaar TC; Philips S; Montgomery EA; Hafez MJ; Powell M; Liu G; Forastiere AA; Benson AB; Kleinberg LR; Murphy KM
Cancer Chemother Pharmacol; 2011 Oct; 68(4):863-70. PubMed ID: 21286719
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group.
Yoon HH; Catalano PJ; Murphy KM; Skaar TC; Philips S; Powell M; Montgomery EA; Hafez MJ; Offer SM; Liu G; Meltzer SJ; Wu X; Forastiere AA; Benson AB; Kleinberg LR; Gibson MK
BMC Cancer; 2011 May; 11():176. PubMed ID: 21586140
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
13. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
